Press Room

News / Jul 03, 2017

Diane Villax receives Scientific Merit Medal

National Science and Technology Meeting, Science 2017, in Lisbon, Portugal

Diane Villax Award Scientific Merit Medal | Hovione

Diane Villax, Founder Chairman, received the Scientific Merit Medal, from the Portuguese Minister of Science, Technology and Higher Education of Portugal, Manuel Heitor, at the opening session of the National Science and Technology Meeting, Science 2017, in Lisbon, Portugal.

The scientific merit medal rewards national or foreign individuals who, due to their outstanding professional qualities and the fulfillment of their duties, have made a valuable and exceptional contribution to the development of science or scientific culture in Portugal.

«It is for me a great honour to represent Hovione on this occasion and to see that our original project has continued and grown and is today recognized at the highest levels. I would like to share and dedicate this moment to my family and to all of Hovione’s Team Members, and especially to the memory of my husband Ivan, who 58 years ago was a visionary and believed that it was possible to create in Portugal an innovative, research-based company» said Diane Villax after the ceremony.

 

Watch Diane Villax interview (in Portuguese):

Diane Villax receives Scientific Merit Medal Video | Hovione

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026